Knockdown of ADAM10 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis

DAN LI1, ZHITAO XIAO2, GANG WANG3 and XIANJI SONG3

1Department of Radiology, The First Teaching Hospital of Jilin University; 2Department of Engineering Mechanics, Jilin University, Changchun, Jilin 130021; 3Department of Orthopaedics, The Third Teaching Hospital of Jilin University, Changchun, Jilin 130033, P.R. China

Received September 19, 2014; Accepted June 5, 2015

DOI: 10.3892/mmr.2015.4011

Abstract. Rheumatoid arthritis (RA) is a systemic autoimmune disease with high rates of morbidity and mortality. Previous studies proposed that the A disintegrin and metalloprotease (ADAM) family is involved in the regulation of inflammation and arthritis. Thus, the present study investigated whether ADAM10 is involved in the progression of RA. The effects of ADAM10 small interfering (si)RNA on the expression levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and chemokine (C-X-C motif) ligand 16 (CXCL16) were determined in fibroblast-like synoviocytes (FLS). In addition, the effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro. The therapeutic efficacy and side-effects of ADAM10 siRNA on cell proliferation, invasion and migration in human RA-FLS were assessed in vitro.
investigated, in addition to observations of cell proliferation, migration and invasion in vitro.

Materials and methods

Patients and isolation of FLS. Written informed consent was obtained from individual patients and the experimental protocol was approved by the Medical Ethics Committee of the Third Teaching Hospital of Jilin University (Changchun, China). RA-FLS were obtained from three patients with RA who underwent a synovectomy. RA-FLS were isolated from synovial tissues by enzymatic digestion, as previously described (17). FLS were grown in Dulbecco's modified Eagle's medium (Gibco Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Invitrogen Life Technologies, Carlsbad, CA, USA), supplemented with 100 µg/ml streptomycin and 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO, USA) in a humidified incubator at 37°C under 5% CO₂. RA-FLS cells used for the experiments were at the third to sixth passage.

FLS transfection. The control and ADAM10-specific siRNA were obtained from Shanghai GenePharma (Shanghai, China). When RA-FLS reached 70-90% confluence, the cells were transfected with ADAM10 siRNA or control siRNA using Lipofectamine 2000 reagent (Invitrogen Life Technologies) according to the manufacturer's instructions. The efficacy of ADAM10 silencing was determined by western blot analysis.

Measurement of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and CXCL16 production. In order to measure TNF-α, IL-6, IL-8 and CXCL16 production, the cells were pretreated with ADAM10 siRNA for 8 h followed by stimulation with 10 µg/ml lipopolysaccharide (LPS; Sigma-Aldrich) for 24 h. The culture supernatants were harvested by centrifugation at 1,000 x g for 5 min at room temperature, 24 h subsequent to LPS stimulation, and the concentrations of TNF-α, IL-6, IL-8 and CXCL16 were measured using ELISA kits for human TNF-α, IL-6, IL-15 and CXCL16 (Bio-Techne, Minneapolis, MN, USA) according to the manufacturer's instructions. The concentration of each was normalized relative to the total number of cells.

Cell proliferation. To measure the effect of ADAM10 siRNA on cell proliferation, the 5-bromo-2-deoxyuridine (BrdU) assay (Merck Millipore, Darmstadt, Germany) was conducted. Briefly, RA-LFS were transfected with ADAM10 siRNA and control SiRNA for 24 h, followed by stimulation with 10 µg/ml LPS for 48 h. Subsequently, cell proliferation was detected by the BrdU Cell Proliferation assay kit according to the manufacturer's instructions.

Cell migration and invasion assay. To assess the effect of ADAM10 siRNA on cell migration and invasion using Transwell insert chambers (Corning Incorporated, New York, NY, USA). For the migration assay, RA-LFS were transfected with ADAM10 siRNA and control siRNA for 24 h, followed by stimulation with 10 µg/ml LPS for 48 h. The cells (1x10⁵) were then plated in the upper chamber in serum-free medium, in triplicate. Medium containing 20% FBS in the lower chamber served as the chemotactrant. Subsequent to culture for 24 h, the media was removed from the upper chamber by wiping with a cotton swab and the cells that had migrated to the lower surface of the filter were fixed in 70% ethanol for 30 min and stained with 0.2% crystal violet (Sigma-Aldrich) for 10 min. Cell migration was measured by counting five randomly selected fields per filter under a light microscope (Olympus, Tokyo, Japan).

For the invasion assay, 3x10⁶ cells were seeded into upper chambers pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) in serum-free medium, in triplicate, and the subsequent steps were the same as those of the aforementioned migration assay up until the cells were stained with crystal violet. The number of cells invading the Matrigel was measured in five randomly selected fields using an inverted microscope (X51; Olympus, Tokyo, Japan).

Western blot analysis. Cells were lysed by incubation on ice for 30 min in lysis buffer containing the Complete Protease Inhibitor Cocktail (Roche Diagnostics GmbH, Mannheim, Germany). Equal quantities of protein (15 µg/lane) from the cell lysates were separated on an 8-15% SDS-PAGE (Invitrogen Life Technologies) and transferred onto nitrocellulose membranes (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The membrane was incubated for 2 h in phosphate-buffered saline (PBS; Sigma-Aldrich) plus 0.1% Tween-20 (Sigma-Aldrich) and 5% nonfat milk to block non-specific binding. The membranes were then incubated with the following mouse monoclonal primary antibodies: Anti-ADAM10 (1:1,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-28358), anti-phosphorylated (p)-AKT (Ser473; 1:1,000; cat. no. 4228), anti-p-PI3K (Tyr458; 1:1,000; cat. no. 4249) and anti-β-actin (1:8,000; cat. no. 3700; all from Cell Signaling Technology, Inc., Danvers, MA, USA) at room temperature for 2 h. Following washing with PBS, the anti-mouse secondary horseradish peroxidase-conjugated antibody (1:10,000; GE Healthcare Life Sciences, Uppsala, Sweden) was added for 2 h. Protein bands were visualized with enhanced chemiluminescence reagent (GE Healthcare Life Sciences, Velizy-Villacoublay, France).

Initiation of CIA and treatment of CIA with ADAM10 siRNA in vivo. Thirty male DBA/1 mice (age, 6-8 weeks; weight, 200-250 g) were purchased from the Institute of Laboratory Animal Science of Jilin University (Changchun, China). All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and with the approval of the Institutional Animal Ethics Committee of Jilin University. Mice were immunized on day zero and boosted on day seven with an intradermal injection of bovine type II collagen in Freund's adjuvant (Sigma-Aldrich) as described previously (17).

Complexes of siRNA and atelocollagen [Boppard (Beijing) Co., Ltd., Beijing, China] were prepared as previously described (18). Subsequently, siRNA/atelocollagen complexes (0.5 mg/kg body weight) were administered to the CIA mice twice per week for 3 weeks, as previously described (19).
Arthritic score. Clinical arthritic scoring was performed every three days according to the following scoring system (19,20): 0, Normal; 1, mild, but definite swelling of either the ankle or digits; 2, moderate redness and swelling of an ankle ± any number of digits; 3, maximal redness and swelling of the entire paw and digits with or without ankylosis. The maximum score per paw was 3 with a total score of 12 per mouse.

Measurement of vascular endothelial growth factor A (VEGF-A), matrix metalloproteinase (MMP)-3 and MMP-9 levels in vitro and in vivo. For the measurement of VEGF-A, MMP-3 and MMP-9 levels in the supernatants, RA-FLS cells were seeded at a density of 2x10^6 cells/ml and pretreated with ADAM10 siRNA for 24 h followed by stimulation with LPS for 48 h. Cell supernatants were centrifuged at 1,000 x g for 5 min at room temperature to remove any cell debris prior to ELISA analysis. The mice were sacrificed by cervical dislocation upon completion of the experiment and ELISA was performed to determine the levels of VEGF-A, MMP-3 and MMP-9, using specific ELISA kits (R&D Systems China Co., Ltd., Shanghai, China) according to the manufacturer's instructions.

Statistical analysis. Data are expressed as the mean ± standard deviation. The differences between groups were analyzed by one-way analysis of variance and post hoc analysis with Dunnett's multiple comparison test and Student's t-tests using GraphPad Prism version 5.01 (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Knockdown of ADAM10 inhibits ADAM10 expression in RA-FLS. To evaluate the silencing capacity of ADAM10, RA-FLS cells were transfected with ADAM10 siRNA and control siRNA, and the effect of ADAM10 silencing was characterized by western blot analysis two days post-transfection. As presented in Fig. 1, transfection with control siRNA did not modulate the levels of ADAM10 expression in RA-FLS cells, as compared with control RA-FLS cells. By contrast, transfection with ADAM10 siRNA significantly reduced the levels of ADAM10 expression in RA-FLS cells compared with control RA-FLS cells (P<0.01).

ADAM10 siRNA inhibits LPS-induced TNF-α, IL-6, IL-8 and CXCL16 expression in RA-FLS. To quantify TNF-α, IL-6, IL-8 and CXCL16 production, RA-FLS were pretreated with ADAM10 siRNA for 24 h followed by stimulation with human LPS for 48 h, then ELISA assays were performed. The results indicate that transfection of ADAM10 siRNA significantly reduces the production of TNF-α, IL-6, IL-8 and CXCL16 in human LPS-induced RA-FLS cells, when compared with cells transfected with control siRNA (Fig. 2; P<0.05).

ADAM10 siRNA inhibits LPS-induced RA-FLS proliferation, migration and invasion of cells. RA-FLS were pretreated with ADAM10 siRNA for 24 h followed by stimulation with human LPS for 48 h. Subsequently, the impact of ADAM10 silencing on the proliferation, migration and invasion of RA-FLS was characterized by BrdU assays, and Transwell migration and invasion assays, respectively. BrdU assays indicated that ADAM10 siRNA significantly repressed LPS-induced RA-FLS proliferation (Fig. 3A; P<0.01). In addition, it was demonstrated that the numbers of migrated ADAM10 siRNA RA-FLS were significantly reduced when compared with the control cells (Fig. 3B; P<0.01). A similar pattern in the numbers of invaded cells was observed in the different groups of RA-FLS (Fig. 3C; P<0.01). Hence, knockdown of ADAM10 expression appeared to inhibit the proliferation, migration and invasion of LPS-induced RA-FLS in vitro.

ADAM10 siRNA inhibits the activation of the PI3K/AKT pathway in RA-FLS cells. To elucidate the underlying mechanisms of the action of ADAM10 silencing in inhibiting the proliferation, migration and invasion of human RA-FLS cells, the impact of ADAM10 silencing on the PI3K/AKT pathway...
in RA-FLS was evaluated. As presented in Fig. 4, compared with control RA-FLS and RA-FLS transfected with control siRNA, silencing ADAM10 resulted in a significant suppression of the phosphorylation of PI3K and AKT in LPS-induced RA-FLS cells, without alteration of the total PI3K and AKT protein levels in the different groups. Thus indicating that knockdown of ADAM10 expression inhibits the PI3K/AKT pathway in human RA-FLS.

**ADAM10 siRNA reduced the arthritis score in CIA mice.** The effect of silencing ADAM10 on the arthritis score in the CIA mouse model was investigated. The arthritis score was evaluated every three days. Treatment with ADAM10 siRNA was initiated on day 22 following the first immunization, when clear onset of arthritis had occurred. It was observed that silencing of ADAM10 reduced the arthritis score of CIA in mice during the treatment (Fig. 5; P<0.05).

**ADAM10 siRNA inhibited the expression of VEGF-A, MMP-3, and MMP-9 in vitro and in vivo.** Invasion-associated proteins including VEGF-A, MMP-3 and MMP-9 were investigated in human RA-FLS. The cells were pretreated...
Figure 5. Silencing ADAM10 reduced the arthritis score in CIA mice. The arthritis score was evaluated every three days. Treatment with ADAM10 siRNA was initiated on day 22 following the first immunization, when clear onset of arthritis had occurred. *P<0.05, **P<0.01 vs. CIA rats. ADAM10, A disintegrin and metalloprotease 10; CIA, collagen-induced arthritis; siRNA, small interfering RNA.

Figure 6. Silencing ADAM10 inhibited the expression of VEGF-A, MMP-3 and MMP-9 in vitro and in vivo. (A) Rheumatoid arthritis fibroblast-like synoviocytes were pretreated with ADAM10 siRNA for 24 h and exposed to human LPS for 48 h. VEGF-A, MMP-3 and MMP-9 were measured using the ELISA at a wavelength of 490 nm. *P<0.01 vs. control siRNA. ADAM10, A disintegrin and metalloprotease 10; siRNA, small interfering RNA; VEGF-A, vascular endothelial growth factor A; MMP, matrix metalloproteinase; LPS, lipopolysaccharide.

with ADAM10 siRNA for 24 h followed by stimulation with human LPS for 48 h. The collected supernatants were then assayed for VEGF-A, MMP-3 and MMP-9. Results of ELISA demonstrated that ADAM10 silencing substantially reduced the expression levels of VEGF-A, MMP-3 and MMP-9 in the supernatants when compared with those of the controls (Fig. 6A; P<0.01).

In addition, the production of VEGF-A, MMP-3 and MMP-9 in the serum of CIA model mice was investigated. It was identified that ADAM10 siRNA inhibits the production of serum VEGF-A, MMP-3 and MMP-9, when compared with control-treated mice (Fig. 6B; P<0.01).

Discussion

It is widely accepted that RA-FLS secrete multiple cytokines and growth factors (such as VEGF) that contribute to the activation of an autocrine loop, resulting in further FLS hyperplasia (21). It has also been demonstrated that RA-FLS migrate and invade into the cartilage and bone, leading to pannus formation and tissue damage during the pathogenic process of RA (22-24). Thus, it is important to identify factors that regulate the migration and invasion of RA-FLS. In the present study, the results demonstrated that transfection with ADAM10 siRNA effectively reduced the levels of ADAM10 expression in human RA-FLS. Furthermore, the results indicated that knockdown of ADAM10 expression inhibited the proliferation, migration and invasion of RA-FLS. In addition, it was observed that knockdown of ADAM10 in RA-FLS inhibited the VEGF-A, MMP-3 and MMP-9 expression levels and the activation of PI3K/AKT signaling. These data imply that ADAM10 may positively regulate the migration and invasion of human RA-FLS. Hence, ADAM10 may serve as a novel therapeutic target for treatment of RA.

Cytokines have been reported to be involved with the progression of RA and perform pathogenic roles in the establishment of rheumatoid synovitis (24,25). TNF-α is a key inflammatory cytokine involved in the pathogenesis of RA, and inhibition of TNF-α expression by antagonism or the use of therapeutic agents is an effective treatment for RA (26,27). IL-6 is present at high concentrations in the serum and synovial fluid of patients with RA (28,29), and serves a key role in the pathogenesis of RA, including osteoporosis and an increased concentration of IL-6 in the joints around the body (28). Increasing evidence indicates that the ADAM family is involved in the regulation of inflammatory responses, and that members of this family may serve as novel therapeutic targets for the treatment of inflammatory disorders, including RA (30). Therefore, the aim of the present study was to determine whether the expression of ADAM10 was associated with inflammatory conditions in human RA-FLS. The results of the current study demonstrate that downregulation of ADAM10 expression inhibits the expression of TNF-α, IL-6, IL-8 and CXCL16 in LPS-induced RA-FLS cells. Therefore, ADAM10 may have potential for use as a therapeutic tool in the treatment of patients with RA who are resistant to anti-cytokine therapeutic strategies.

ADAM10, a member of the ADAM family, has been demonstrated to be involved in numerous cell processes, including proliferation, differentiation, migration and invasion (31,32). A previous study identified that ADAM10 is important in modulating the chemosensitivity of hepatocellular carcinoma cells, which involves activation of the PI3K/AKT signaling...
pathway (33). Accumulating evidence demonstrates that the PI3K/AKT signaling pathway positively regulates the migration and invasion of various types of cells (34,35). The results of the current study demonstrate that knockdown of ADAM10 inhibits PI3K and AKT phosphorylation, and attenuates spontaneous migration and invasion, as well as VEGF-A, MMP-3 and MMP-9 expression in human RA-FLS. MMPs have been reported to be involved in the degradation of extracellular matrix components and significant contributors to joint destruction during the process of RA (35-37). Therefore, it was hypothesized that therapeutic targeting of ADAM10 may result in the suppression of migration and invasion of human RA-FLS via the inhibition of PI3K/AKT activation, MMP-2 and MMP-9 expression.

In conclusion, the data from the present study demonstrate that knockdown of ADAM10 inhibits the production of inflammatory cytokines, the activation of PI3K/AKT signaling, and the expression of VEGF-A, MMP-3 and MMP-9 in LPS-induced RA-FLS, as well as inhibiting human RA-FLS proliferation, migration and invasion in vitro. In addition, knockdown of ADAM10 was found to reduce the arthritis score and serum levels of VEGF-A, MMP-3 and MMP-9 in vivo. These observations present novel evidence that ADAM10 may serve as a novel target for treatment of RA.

References

